Skip to main content

Table 4 Upper respiratory tract and other characteristics before initiation of anti-IL5/IL5R or anti-IgE treatment. The time of use describes mean time of use of biological therapy in months

From: A comparison of biologicals in the treatment of adults with severe asthma – real-life experiences

Characteristics Anti-IL5/IL5R Anti-IgE
Reslizumab, Mepolizumab, Benralizumab, n = 38 Omalizumab, n = 17
Asthma (number, (%)) 38 (100) 17 (100)
Nasal polyposis as only indication for biological therapy (number, (%)) 3 (8) 0 (0)
Time of use (months) a 12.4 (1–29. SD 7.6) 43.8 (5–109. SD 35.6)
Age at analysis (years) 54.2 (25–72. SD 10.8) 47.6 (28–76. SD 11.5)
Women (number, (%)) 18 (47) 12 (71)
BMIb (kg/m2) 28.1 (16.9–38.8. SD 4.8) 27.6 (23–35. SD 3.3)
Use of intranasal corticosteroids (number, (%)) 34 (89) 14 (82)
Use of oral antihistamine (number, (%)) 13 (34) 8 (47)
Use of montelukast (number, (%)) 27 (71) 9 (53)
Positive skin prick test or allergen specific serum IgE (number, (%)) 16 (42) 17 (100)
Smokers (number, (%)) 1 (3) 0 (0)
Ex-smokersc (number, (%)) 9 (24) 2 (12)
Nasal polyposis (number, (%)) 29 (76) 11 (65)
Chronic rhinosinusitis (CRSwNP or CRSsNP) (number, (%)) 34 (89) 15 (88)
ASA intolerance (number, (%)) 9 (24) 3 (18)
Osteoporosis (number, (%)) 12 (32) 4 (24)
Blood eosinophil count (E9/l) 0.48 (0.00–1.84. SD 0.38) 0.50 (0.01–1.21. SD 0.42)
  1. aTime of use of biological therapy
  2. bBMI = Body mass index
  3. cDefined as previous daily smoking at minimum 1 year